Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells

J Hepatol. 2004 Feb;40(2):278-84. doi: 10.1016/j.jhep.2003.09.021.

Abstract

Background/aims: Human hepatoma cells have been reported to be resistant to Fas-mediated apoptosis. Sodium butyrate (SB) induced apoptosis of several cancer cells. We investigated the effects of SB on Fas-mediated apoptosis of hepatoma cells.

Methods: In hepatoma cells (HuH-6, HuH-7, Hep-G2, and PLC/PRF/5), susceptibility to Fas-mediated apoptosis and Fas expression were assessed. Caspase-3 activation and cell cycle progression were evaluated in HuH-6. A cDNA microarray assay was performed to screen the changes in the expression of mRNAs.

Results: Pretreatment with SB caused an enhancement of the sensitivity to anti-Fas-mediated cytotoxicity, though it did not increase the expression of Fas. The cDNA microarray assay revealed up-regulation of pro-apoptotic Bik, Bak, Bid and c-Jun N-terminal protein kinase-1, and down-regulation of anti-apoptotic Bag-1 and cellular Fas-associated death domain-like interleukin-1beta-converting enzyme inhibitor protein. In some molecules, expression of the proteins was confirmed by Western blotting. An increase in truncated-Bid accompanying the reduction in Bid was also observed.

Conclusions: SB enhances the susceptibility of hepatoma cells to anti-Fas-mediated cytotoxicity by altering the mRNA and protein expression and/or the activation status of proteins that could be involved in the Fas signaling pathway. SB may have an important role in the elimination of hepatoma cells.

MeSH terms

  • Apoptosis / drug effects*
  • Apoptosis / physiology
  • Butyrates / pharmacology*
  • Carcinoma, Hepatocellular*
  • Cell Line, Tumor / cytology
  • Cell Line, Tumor / drug effects
  • Cell Line, Tumor / physiology
  • Flow Cytometry
  • Gene Expression Regulation, Neoplastic / drug effects
  • Histone Deacetylase Inhibitors
  • Humans
  • Liver Neoplasms*
  • Oligonucleotide Array Sequence Analysis
  • fas Receptor / metabolism*

Substances

  • Butyrates
  • Histone Deacetylase Inhibitors
  • fas Receptor